Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
P. Sardari Nia, C. Colpaert, P. Vermeulen, E. Van Marck, P. Van Schil (Antwerp, Belgium). Carbonic anhydrase 9 expression (CA9e) profile combined with growth patterns (GPs) in non-small cell lung cancer (NSCLC) identifies a group of patients with an extremely poor prognosis. Eur Respir J 2005; 26: Suppl. 49, 184

Member's Comments

No comment yet.

Related content which might interest you: Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Quantitative RT-PCR 3-gene expression signature predicts survival in early-stage non-small cell lung cancer (NSCLC) patients (pts) Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Gene expression profiling in non-small cell lung cancer (NSCLC) according to smoking status Source: Annual Congress 2008 - Discovery of novel targets in lung disease by means of functional genomics Year: 2008